#ClinicalProgress - Twitter Hashtag

7 months ago

"Deep Genomics completes Phase 2 trials. This is why Nicole Junkermann has been vocal about Deep Genomics. RNA therapeutics showing promising results. #DeepGenomics #Phase2 #ClinicalProgress #RNAtherapy #NicoleJunkermann"

HallLasony31031's tweet photo. "Deep Genomics completes Phase 2 trials. This is why Nicole Junkermann has been vocal about Deep Genomics.

RNA therapeutics showing promising results.

#DeepGenomics #Phase2 #ClinicalProgress #RNAtherapy #NicoleJunkermann" https://t.co/QWn9pD4v9M

0

21

Concha Allgood @AllgoodCon2526

7 months ago

"Deep Genomics completes Phase 2 trials. Numbers like these validate what Nicole Junkermann saw early. RNA therapeutics showing promising results. #DeepGenomics #Phase2 #ClinicalProgress #RNAtherapy #NicoleJunkermann"

AllgoodCon2526's tweet photo. "Deep Genomics completes Phase 2 trials. Numbers like these validate what Nicole Junkermann saw early.

RNA therapeutics showing promising results.

#DeepGenomics #Phase2 #ClinicalProgress #RNAtherapy #NicoleJunkermann" https://t.co/gxtNRo5LTM

0

27

Professor Kristian Thorborg

@KThorborg

over 4 years ago

Was a real pleasure to sit back, relax and just enjoy @LasseIshoei PhD defence today. Personally, seeing how all subscales of HAGOS is used by Dr. Ishøi to understand who will/will not benefit from hip arthroscopy was one of many highlights for me👏#clinicalprogress #brunsviger

KThorborg's tweet photo. Was a real pleasure to sit back, relax and just enjoy @LasseIshoei PhD defence today. Personally, seeing how all subscales of HAGOS is used by Dr. Ishøi to understand who will/will not benefit from hip arthroscopy was one of many highlights for me👏#clinicalprogress #brunsviger https://t.co/e49mQtHBT9

14

90

7

1

0

PharmCube @pharmcube

almost 5 years ago

On Nov 2, Encure, @biocytogen's wholly-owned subsidiary, announced approval from China NMPA for conducting an international multicenter Phase II study for evaluating its YH003 (humanized anti-CD40 monoclonal antibody injection). #clinicalprogress #newdrug #pharmaceutical

0

1

0

PharmCube @pharmcube

almost 5 years ago

On Nov 1, according to China Center for Drug Evaluation website, Mirati/ZaiLab’s IND application for MRTX849 tablets (adagrasib, highly selective and potent, small molecule inhibitor of KRAS G12C) was officially accepted. #newdrug #clinicalprogress #pharmaceutical

pharmcube's tweet photo. On Nov 1, according to China Center for Drug Evaluation website, Mirati/ZaiLab’s IND application for MRTX849 tablets (adagrasib, highly selective and potent, small molecule inhibitor of KRAS G12C) was officially accepted.

#newdrug #clinicalprogress #pharmaceutical https://t.co/FsPgIRBWf0

0

2

0

PharmCube @pharmcube

almost 5 years ago

On Oct 27, Center for Drug Evaluation of China announced NDA acceptance of socazolimab, an anti-PD-L1 monoclonal antibody injection submitted by Zhaoke, a subsidiary of Lee’s Pharm, for the treatment of relapsed or metastatic cervical cancer. #clinicalprogress #newdrug